CalciMedica (CALC) Stock: Buy, Sell, or Hold?
CALC - CalciMedica, Inc. Common Stock
$1.86
-0.06 (-3.12%)
âŧ
5d:
-7.0%
30d:
+218.93%
90d:
+138.13%
WAIT
LOW Confidence
Analysis Updated: Sep 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CALC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CALC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CALC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CALC is currently trading at $1.86, which is considered slightly high relative to its 30-day fair value range of $0.70 to $2.16.
Technical Outlook: Technically, CALC is in a uptrend. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CALC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $50.00 (+2588.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CALC is in a uptrend. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CALC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $50.00 (+2588.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.70 -
$2.16
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 2588.2% below Wall St target ($50.00)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.70 -
$2.16
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.86
Resistance Level
$2.31
Current Trend
Uptrend
Technical data as of
Sep 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.35
Wall Street Target
$50.00
(+2588.2%)
Share & Embed Analysis
Last updated: September 22, 2026 9:08 AM ET
Data refreshes hourly during market hours. Next update: 10:08 AM
Data refreshes hourly during market hours. Next update: 10:08 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CALC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 66 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 68 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 55 HOLD |
